 |
|
 |
|
| What we do |
|
|
|
The mission of VacZine Analytics is simple. We seek to enable vaccine clients to make better-informed decisions.
We produce a range of products and services to support broad day-to-day activities such as:
» Disease analysis
- identification of key trends, issues and dynamics
» Building new business
- new product strategy/R&D prioritization
» Growing existing
business - lifecycle management opportunities
» Finding new business
- commercial due diligence/horizon scanning
» Planning the future
- strategic planning/internal consultation
View our company flipping book brochure
|
|
| In the Press |
|
|
|
Find out about VacZine Analytics contribution to major journal and press articles:
» Sheridan C. Vaccine Market Boosters, Nature Biotechnology. June 2009, Volume 27 No 6 pp502-578
» Schomann-Finck C. Neue Euphorie. Money Maker. Focus Money Magazine (German), Issue 26, 2009
» Lucero CA., et al. Evaluating the potential public health impact of a Staphylococcus aureus vaccine
through use of population-based surveillance for invasive methicillin-resistant
S. aureus disease in the United States. Vaccine. 2009 - In Press
» Sheridan C. Will J&J turbocharge Crucell's vaccine portfolio? Nature Biotechnology. December 2010, Volume 28 No 12 pp1223-1224
|
|
|
|
|
